Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

NCT05828589 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

NCT00923507 ·Status: RECRUITING

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

NCT04566978 ·Status: COMPLETED ·Phase: EARLY_PHASE1

FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

NCT04555811 ·Status: COMPLETED ·Phase: PHASE1

Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors

NCT00001301 ·Status: COMPLETED

Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma

NCT00582270 ·Status: COMPLETED

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

NCT01996865 ·Status: COMPLETED ·Phase: PHASE3

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

NCT04982471 ·Status: TERMINATED

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

NCT00307177 ·Status: COMPLETED ·Phase: PHASE2

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

NCT02856646 ·Status: COMPLETED

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

NCT00482053 ·Status: TERMINATED ·Phase: PHASE2

Causes of Death in Follicular Lymphoma: a Single Center Retrospective Analysis

NCT02951871 ·Status: COMPLETED

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

NCT05940272 ·Status: RECRUITING ·Phase: NA

BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.

NCT06424379 ·Status: ACTIVE_NOT_RECRUITING

B-cell Chronic Lymphoid Malignancies Markers

NCT04952974 ·Status: UNKNOWN

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.

NCT05888701 ·Status: UNKNOWN

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

NCT05834751 ·Status: UNKNOWN ·Phase: NA

A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

NCT01221571 ·Status: COMPLETED ·Phase: PHASE1

A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types

NCT05907447 ·Status: UNKNOWN

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

NCT05683171 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

NCT00347971 ·Status: COMPLETED ·Phase: PHASE1

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

NCT05861050 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies

NCT04684979 ·Status: WITHDRAWN ·Phase: PHASE2

Prospective Study of Lymphoproliferative Diseases

NCT01704742 ·Status: WITHDRAWN

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

NCT05883449 ·Status: TERMINATED ·Phase: PHASE2